Clinical Oncology evaluations can include various molecular tests and the results can influence patient care. One example of an Oncology Molecular Diagnostic is mutation analysis for genes known to be confer a high risk of cancer such as BRCA1/2. Healthy patients found to carry this mutation benefit from increased screening and surveillance due to their increased risk of several cancers.
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
The laboratory diagnosis of infectious diseases has traditionally relied on recovery of pathogens in cultures and for many infections, this approach remains the standard of care. The developm...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
As reimbursement changes and healthcare moves towards value-based models, the clinical laboratory is faced with the challenge of redefining its value outside the cost per test. This session...
Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions fo...
Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. We combine the RNA- targeting CRISPR effector Cas13 with...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies av...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
DATE: January 16th, 2019TIME: 9:00AM PDT, 12:00PM EDTDr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care,to examine pat...
DATE: November 20, 2018TIME: 07:00 PSTSince its original development (2008) COLD-PCR has been used by several groups for increasing the sensitivity of mutation detection in di...
In 2017, the Washington State Legislature passed HB 1427, which mandated that boards and commissions for five prescribing professions (dental, medical, nursing, osteopathic, and podiatric) en...
Drug overdose surpassed motor vehicle accidents as the leading cause of accidental death 2006 and has remained the leading cause of accidental death at the state and national level. Mos...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
The laboratory diagnosis of infectious diseases has traditionally relied on recovery of pathogens in cultures and for many infections, this approach remains the standard of care. The developm...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
As reimbursement changes and healthcare moves towards value-based models, the clinical laboratory is faced with the challenge of redefining its value outside the cost per test. This session...
Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions fo...
Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. We combine the RNA- targeting CRISPR effector Cas13 with...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies av...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
DATE: January 16th, 2019TIME: 9:00AM PDT, 12:00PM EDTDr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care,to examine pat...
DATE: November 20, 2018TIME: 07:00 PSTSince its original development (2008) COLD-PCR has been used by several groups for increasing the sensitivity of mutation detection in di...
In 2017, the Washington State Legislature passed HB 1427, which mandated that boards and commissions for five prescribing professions (dental, medical, nursing, osteopathic, and podiatric) en...
Drug overdose surpassed motor vehicle accidents as the leading cause of accidental death 2006 and has remained the leading cause of accidental death at the state and national level. Mos...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
